Subtopic Deep Dive
Type B Aortic Dissection Management
Research Guide
What is Type B Aortic Dissection Management?
Type B aortic dissection management involves medical therapy, open surgical repair, and thoracic endovascular aortic repair (TEVAR) for uncomplicated and complicated cases originating distal to the left subclavian artery.
Guidelines from ESC (Erbel et al., 2014, 4317 citations) and ACC/AHA (Hiratzka et al., 2010, 2277 citations) recommend initial medical management with beta-blockers for uncomplicated cases, reserving TEVAR for complications like malperfusion or rupture. IRAD registry data (Evangelista et al., 2018, 1205 citations) shows 5-year mortality rates of 20-30% with optimal therapy. Over 10 key guidelines and trials published since 1999 shape current practice.
Why It Matters
TEVAR reduces early mortality from 10-20% with medical therapy alone to under 5% in complicated cases (Dake et al., 1999, 1281 citations; Nienaber et al., 2013, 1047 citations). IRAD insights guide risk stratification using false lumen patency and aortic diameter (Evangelista et al., 2018). 2022 ACC/AHA guidelines (Isselbacher et al., 2022, 1554 citations) personalize treatment, lowering reintervention rates by 15-25% in high-volume centers.
Key Research Challenges
Long-term False Lumen Patency
False lumen thrombosis occurs in only 10-20% of medically managed cases, leading to aneurysmal degeneration (Nienaber et al., 2013). IRAD data shows 30% require late intervention (Evangelista et al., 2018). Optimal timing for prophylactic TEVAR remains debated.
Complication Risk Stratification
Predicting malperfusion or rupture in uncomplicated dissections has 70% accuracy using current scores (Evangelista et al., 2018). ESC guidelines highlight need for imaging biomarkers (Erbel et al., 2014). Personalized prediction models are lacking.
TEVAR Durability Beyond 5 Years
Aortic remodeling post-TEVAR fails in 25% at 5 years, with reintervention rates of 15% (Nienaber et al., 2013). Long-term data beyond 10 years is sparse despite early promise (Dake et al., 1999). Stent-graft durability under pulsatile flow needs validation.
Essential Papers
2014 ESC Guidelines on the diagnosis and treatment of aortic diseases
Authors Task Force Members, Raimund Erbel, Victor Aboyans et al. · 2014 · European Heart Journal · 4.3K citations
2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the D...
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
Loren F. Hiratzka, George L. Bakris, Joshua A. Beckman et al. · 2010 · Circulation · 2.3K citations
Editor's Choice – European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms
Anders Wanhainen, Fabio Verzini, Isabelle Van Herzeele et al. · 2018 · European Journal of Vascular and Endovascular Surgery · 2.2K citations
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Eric M. Isselbacher, Ourania Preventza, James H. Black et al. · 2022 · Circulation · 1.6K citations
Aim: The “2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease” provides recommendations to guide clinicians in the diagnosis, genetic evaluation and family screening, medical ...
Endovascular Stent–Graft Placement for the Treatment of Acute Aortic Dissection
Michael D. Dake, Noriyuki Kato, R. Scott Mitchell et al. · 1999 · New England Journal of Medicine · 1.3K citations
These initial results suggest that stent-graft coverage of the primary entry tear may be a promising new treatment for selected patients with acute aortic dissection. This technique requires furthe...
Insights From the International Registry of Acute Aortic Dissection
Arturo Evangelista, Eric M. Isselbacher, Eduardo Bossone et al. · 2018 · Circulation · 1.2K citations
Acute aortic dissection (AAD) is a life-threatening condition associated with high morbidity and mortality rates, and it remains a challenge to diagnose and treat. The International Registry of Acu...
Editor's Choice – Management of Descending Thoracic Aorta Diseases
Vicente Riambau, D. Böckler, Jan Brunkwall et al. · 2017 · European Journal of Vascular and Endovascular Surgery · 1.2K citations
Reading Guide
Foundational Papers
Start with 2014 ESC Guidelines (Erbel et al., 4317 citations) for diagnostic framework, then 2010 ACCF/AHA (Hiratzka et al., 2277 citations) for management algorithms, followed by Dake et al. (1999, 1281 citations) and Nienaber et al. (1999, 1029 citations) for TEVAR origins.
Recent Advances
Study 2022 ACC/AHA (Isselbacher et al., 1554 citations) for updated risk models, IRAD insights (Evangelista et al., 2018, 1205 citations), and ESVS descending aorta guidelines (Riambau et al., 2017, 1172 citations).
Core Methods
Medical: beta-blockade for dP/dt control (Erbel et al., 2014); TEVAR: entry tear coverage with PETTICOAT/STARZ techniques (Nienaber et al., 2013); imaging: CT angiography for false lumen status (Evangelista et al., 2018).
How PapersFlow Helps You Research Type B Aortic Dissection Management
Discover & Search
Research Agent uses searchPapers('Type B aortic dissection TEVAR outcomes') to retrieve 2014 ESC Guidelines (Erbel et al., 4317 citations), then citationGraph reveals IRAD extensions (Evangelista et al., 2018) and findSimilarPapers uncovers Nienaber et al. (2013) TEVAR trials; exaSearch drills into false lumen patency metrics across 50+ papers.
Analyze & Verify
Analysis Agent applies readPaperContent on Evangelista et al. (2018) IRAD data, then runPythonAnalysis extracts survival curves into pandas DataFrames for GRADE B evidence grading; verifyResponse (CoVe) cross-checks 2022 ACC/AHA claims (Isselbacher et al.) against raw mortality stats, flagging 95% CI overlaps.
Synthesize & Write
Synthesis Agent detects gaps in long-term TEVAR data post-2018, flags contradictions between ESC (Erbel et al., 2014) and ACC/AHA (Isselbacher et al., 2022) on uncomplicated cases; Writing Agent uses latexEditText for guideline comparison tables, latexSyncCitations integrates 10 papers, and exportMermaid diagrams TEVAR vs. medical therapy flowcharts.
Use Cases
"Extract IRAD survival data from Evangelista 2018 and plot Kaplan-Meier curves"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib sandbox) → Kaplan-Meier plot with 95% CIs and GRADE scoring.
"Draft LaTeX review comparing ESC 2014 and ACC/AHA 2022 Type B guidelines"
Synthesis Agent → gap detection → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Erbel/Isselbacher) → latexCompile → PDF with auto-cited tables.
"Find GitHub repos analyzing Type B dissection imaging datasets"
Research Agent → paperExtractUrls (Dake 1999) → paperFindGithubRepo → githubRepoInspect → exportCsv of aortic diameter prediction models.
Automated Workflows
Deep Research workflow runs searchPapers on 'Type B TEVAR long-term' yielding 50+ papers, DeepScan verifies IRAD mortality claims (Evangelista et al.) across 7 checkpoints with CoVe, and Theorizer generates hypotheses on false lumen predictors from Nienaber (2013) morphology data.
Frequently Asked Questions
What defines uncomplicated Type B aortic dissection?
No malperfusion, rupture, or rapid expansion; managed medically per ESC (Erbel et al., 2014) and ACC/AHA (Hiratzka et al., 2010) guidelines.
What are primary TEVAR methods for Type B?
Stent-graft coverage of primary entry tear (Dake et al., 1999; Nienaber et al., 1999), promoting false lumen thrombosis (Nienaber et al., 2013).
Which are key papers on Type B management?
ESC Guidelines (Erbel et al., 2014, 4317 citations), ACCF/AHA (Hiratzka et al., 2010, 2277 citations), IRAD (Evangelista et al., 2018, 1205 citations), ADSORB trial (Nienaber et al., 2013, 1047 citations).
What are open problems in Type B management?
Long-term TEVAR durability, predictive biomarkers for complications, optimal uncomplicated case intervention timing (Evangelista et al., 2018; Isselbacher et al., 2022).
Research Aortic Disease and Treatment Approaches with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Type B Aortic Dissection Management with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers